STOCK TITAN

Theravance Biopharma completes $17-per-share merger

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Theravance Biopharma, Inc. (TBPH) completed its merger with Zymeworks Inc. on September 23, 2026, and survived as a wholly owned subsidiary of Zymeworks. The ownership amendment reports that the reporting persons no longer beneficially owned the issuer’s ordinary shares after the merger.

Each ordinary share outstanding immediately before the merger, including shares held by Madison Avenue International LP, was cancelled and converted into the right to receive $17.00 in cash, without interest, and one contingent value right. Madison Avenue International LP, Madison Avenue Partners, LP, EMAI Management, LLC, Madison Avenue GP, LLC, Caraway Jackson Investments LLC and Eli Samaha reported zero beneficially owned shares; the reporting persons ceased to be beneficial owners of more than 5% of the class.

Cash consideration per ordinary share $17.00 in cash Right to receive this amount, without interest, for each ordinary share outstanding immediately before the merger
Contingent value rights per ordinary share 1 contingent value right Right to receive one for each ordinary share outstanding immediately before the merger
Beneficially owned ordinary shares 0 shares Madison Avenue International LP and the other reporting persons reported zero as of September 23, 2026
Reported ownership percentage approximately 0% Reporting persons’ beneficial ownership as of September 23, 2026
Ordinary shares outstanding 51,918,754 shares As of July 31, 2026; basis stated for the ownership percentage
contingent value right financial
"one contingent value right"
A contingent value right is a special security that gives its holder the right to receive one or more future payments only if specified events happen, such as a product reaching a sales target or getting regulatory approval. It matters to investors because it offers potential extra payout tied to uncertain outcomes—like a bet that a project will succeed—so it can add upside to a deal while also carrying extra risk and valuation uncertainty.
beneficially owned financial
"no longer beneficially owned any Ordinary Shares"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did each TBPH ordinary share receive in the merger?

Each ordinary share outstanding immediately before the merger was converted into the right to receive $17.00 in cash, without interest, and one contingent value right.

How many TBPH ordinary shares did the reporting persons own after the merger?

The reporting persons reported zero beneficially owned ordinary shares as of September 23, 2026, and ceased to be beneficial owners of more than 5% of the class.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Madison Avenue International LP
Signature:/s/ Eli Samaha
Name/Title:Eli Samaha, as Manager of Madison Avenue GP, LLC, its General Partner
Date:11/16/2026
Madison Avenue Partners, LP
Signature:/s/ Eli Samaha
Name/Title:Eli Samaha, as Managing Member of EMAI Management, LLC, its General Partner
Date:11/16/2026
EMAI Management, LLC
Signature:/s/ Eli Samaha
Name/Title:Eli Samaha, as Managing Member
Date:11/16/2026
Madison Avenue GP, LLC
Signature:/s/ Eli Samaha
Name/Title:Eli Samaha, as Manager
Date:11/16/2026
Caraway Jackson Investments LLC
Signature:/s/ Eli Samaha
Name/Title:Eli Samaha, as Member
Date:11/16/2026
Eli Samaha
Signature:/s/ Eli Samaha
Name/Title:Eli Samaha
Date:11/16/2026

Keep reading